HUA MEDICINE-B (02552) granted a total of 20 million share purchase rights.

Hua Ling Pharmaceuticals Group-B (02552) announced that on November 28, 2025, the company granted stock options to three executive directors and 71 employees in accordance with the company's stock option plan approved and adopted on August 26, 2018, and effective on September 14, 2018. However, the grantee must accept the stock options before they can be exercised. The stock options grant the grantee the right to subscribe for a total of 20 million new shares in the company's capital, with a par value of $0.001 per share.